{"id": "236949", "url": "https://fevir.net/resources/Group/236949", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"], "versionId": "71", "lastUpdated": "2025-10-07T17:12:54.639Z"}, "type": "person", "title": "SGLT2 inhibitors Group in Adults with type 2 diabetes", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/relates-to", "extension": [{"url": "type", "valueCode": "part-of"}, {"url": "targetReference", "valueReference": {"type": "Composition", "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-conversion-report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}]}, {"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/cite-as", "valueMarkdown": "SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236949. Revised 2025-10-07. Available at: https://fevir.net/resources/Group/236949. Computable resource at: https://fevir.net/resources/Group/236949#json."}], "publisher": "Computable Publishing LLC", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "236949", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "enumerated", "useContext": [{"code": {"code": "evidence-communication", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"code": "ExposureGroup", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "ExposureGroup"}]}}], "description": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors", "resourceType": "Group", "characteristic": [{"code": {"text": "Member of"}, "exclude": false, "description": "inclusion in Adults with type 2 diabetes", "valueReference": {"type": "Group", "display": "Adults with type 2 diabetes and CVD and CKD", "reference": "Group/236947", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-population-group-85394-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}, {"code": {"text": "Exposed to"}, "exclude": false, "description": "received SGLT2 inhibitors", "valueReference": {"type": "Group", "display": "Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors", "reference": "Group/236769", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "MAGIC-5288-j1Wqrn-intervention-85394-I-85798", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}}], "combinationMethod": "all-of"}